Clinically Suspected and Biopsy-Proven Myocarditis Temporally Associated with SARS-CoV-2 Infection
- 27 January 2022
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 73 (1), 149-166
- https://doi.org/10.1146/annurev-med-042220-023859
Abstract
We review current data on clinically suspected [European Society of Cardiology (ESC) 2013 criteria] and biopsy-proven [ESC and World Health Organization (WHO) criteria] myocarditis that is temporally associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ESC/WHO etiological diagnosis of viral myocarditis is based on histological, and immunohistological evidence of nonischemic myocyte necrosis and monolymphocytic infiltration, i.e., myocarditis, plus the identification of a specific cardiotropic virus by molecular techniques, in particular polymerase chain reaction (PCR)/in-situ hybridization, on endomyocardial biopsy (EMB)/autopsy tissue. There is not yet definitive EMB/autopsy proof that SARS-CoV-2 causes direct cardiomyocyte damage in association with histological myocarditis. Clinical epidemiology data suggest that myocarditis is uncommon for both SARS-CoV-2-positive and -negative PCR cases. We hypothesize that the rare virus-negative biopsy-proven cases may represent new-onset immune-mediated or latent pre-existing autoimmune forms, triggered or fostered by the hyperinflammatory state of severe COVID-19. We recommend the application of the ESC/WHO definitions and diagnostic criteria in future reports to avoid low-quality scientific information leading to an inaccurate estimate of myocarditis incidence based on misdiagnosis. Expected final online publication date for the Annual Review of Medicine, Volume 73 is January 2022. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.Keywords
This publication has 104 references indexed in Scilit:
- Viral causes of human myocarditisArchives of Cardiovascular Diseases, 2009
- Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC studyEuropean Heart Journal, 2009
- Usefulness of Immunosuppression for Giant Cell MyocarditisThe American Journal of Cardiology, 2008
- The Role of Endomyocardial Biopsy in the Management of Cardiovascular DiseaseJournal of Invasive Cardiology, 2007
- A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosisEuropean Heart Journal, 2007
- Prospective Familial Assessment in Dilated CardiomyopathyJournal of the American College of Cardiology, 2007
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412The New England Journal of Medicine, 2006
- High Prevalence of Viral Genomes and Multiple Viral Infections in the Myocardium of Adults With “Idiopathic” Left Ventricular DysfunctionJournal of the American College of Cardiology, 2005
- Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of CardiomyopathiesJournal of the American College of Cardiology, 1996
- Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathyJournal of Invasive Cardiology, 1990